Benzinga | Apr 9, 2021 07:55AM EDT

Berenberg Initiates Coverage On BioXcel Therapeutics with Buy Rating, Announces Price Target of $75

Berenberg analyst Anita Dushyanth initiates coverage on BioXcel Therapeutics (NASDAQ:BTAI) with a Buy rating and announces Price Target of $75.